


IQ4I Research & Consultancy published a new report on “Glucose Monitoring Global Market – Forecast To 2023”

Monitoring the blood sugar level on a regular basis and analyzing the results is crucial in managing diabetes. Rise in aging population is driving the market.

BOSTON, MASSACHUSETTS, U.S., March 29, 2018 /EINPresswire.com/ -- Diabetes is a metabolic disease in which the blood glucose, or sugar, levels are too high over a long period. Glucose comes from the foods that are consumed by people and hormone insulin helps the glucose get into the cells to give them energy. Three types of diabetes have been identified they are type 1 diabetes, where in the body does not make insulin. In type 2 diabetes, which is the most common type, the body does not make or use insulin well. Without enough insulin, the glucose stays in the blood. Pregnant women can also get diabetes, called gestational diabetes. Over time, having too much glucose in the blood can cause serious problems such as damage to eyes, kidneys and nerves. Apart from these, diabetes can also cause heart disease, stroke and even the need to remove a limb. If the blood sugar is higher than normal but not high enough to be called diabetes is said to be pre-diabetes puts a patient at a higher risk of getting type 2 diabetes.



Monitoring the blood sugar level on a regular basis and analyzing the results is crucial in treating diabetes. [Self-monitoring](#) of blood glucose level is an integral part of diabetes management because it puts the patient in charge. Regardless of managing diabetes through diet and exercise alone or

“

Glucose Monitoring Global Market estimated to be worth \$11,248.5 million by 2023”

IQ4I Analyst

combined with oral medicines or insulin, the regular blood sugar monitoring provides immediate feedback on how the program is working. Glucose meters are used to self monitor the blood glucose levels at home or at clinics. At hospitals lab analysis such as Hb1Ac, urine are used to monitor the levels of glucose. The glucose monitoring global market is expanding at a steady rate, as estimated by [IQ4I Research](#), the glucose monitoring global market is expected to grow at

low single digit CAGR to reach \$11,248.5 million by 2023.

The global rise in the prevalence and incidence of diabetes, continuous technological advancement, increasing demand for less invasive products, and increase in R&D investments are driving the

market growth. Increase in obesity population due to lifestyle changes, increase in urbanization, untapped markets like Middle East, Africa shows that glucose monitoring market has vast opportunities in the coming years. Frequent product recalls i.e. glucose testing strips due to manufacturing defects or supply of expired test strips and less product differentiation among the self blood glucose monitors are the factors that are restraining the market growth. The limited reimbursement facilities and alternative treatments that include cell based assays, biomarkers identification and artificial pancreas and high cost associated with [Continuous Glucose Monitoring \(CGM\)](#) are threats for the market growth.

Glucose Monitoring global market is classified based on products, sample type, end-users and geography. The products segment is divided into three segments i.e., Invasive, Non-Invasive and lab based glucose monitoring products. The Invasive glucose monitoring products segment accounted the largest share. Non-Invasive glucose monitoring segment is fastest growing segment and is projected to grow at a very high double digit CAGR.

Based on sample type the market is segmented into blood, urine and others. The blood segment accounted the largest share other source based glucose monitoring segment is fastest growing segment Based on the end-user, the glucose monitoring global market is segmented into hospitals, private clinics, home care and ambulatory settings. Among end-users, home care segment accounted for the largest share.

The glucose monitoring global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North America region commanded the largest revenue market share due to favourable reimbursement coverage and high investments in healthcare infrastructures that have led to the market growth in this region. However, Asia-Pacific region is expected to grow at the highest CAGR due to increasing healthcare awareness, higher economic growth, large patient pool and rising aged population.

Some of the technological innovations are no strip, no coding devices, in terms of source for measuring glucose, wireless or wearable products, which are the focus areas, where product advancement is seen in the glucose monitoring devices market.

Non-invasive devices make use of different sources for measuring glucose (urine, tear, saliva, sweat, skin etc) by utilizing various techniques namely optical, transdermal etc. Technologies that monitor glucose levels without compromising the skin barrier or involving the introduction of instruments such as needles into the body is known as non-invasive glucose monitoring methods or devices. There are three general categories of techniques for measuring glucose levels namely optical techniques, transdermal techniques and electrochemical techniques.

Lab based glucose monitoring tests such as Haemoglobin A1c (HbA1c); glucose tolerance test (GTT) and urine analysis is preferred over self monitoring products as a confirmatory test due to accuracy of results. The special features of these lab based glucose monitoring tests are other parameters such as ketone, haemoglobin, sodium levels etc can be monitored which plays decisive role in critically ill patients in emergencies.

The glucose monitoring market is consolidated because the majority of the glucose monitoring market is dominated by players such as Roche, Johnson & Johnson, Abbott, Medtronic, Ascensia, Dexcom, Arkray and BioRad control major share of the market as these companies have a strong distribution networks and have multiple channels to reach the patients, whereas, in CGM market competition is very limited due to technologies being protected by strong IP portfolio.

Major players in glucose monitoring market include Roche (Switzerland), Dexcom (U.S.), B. Braun

Melsungen AG (Germany), Medtronic, Inc. (Ireland), Johnson & Johnson (U.S.), Abbott Laboratories (U.S.), AgaMatrix (U.S.), Arkray (Japan), Ascensia (Switzerland), Trividia Health, Inc (U.S.) etc.

Some of the other companies operating in glucose monitoring global market includes Acon Diabetes Care International (U.S.), Alliance International (Taiwan), Arkray (Japan), Beurer (Germany), Bremed Limited (Hong Kong), Carematix Inc.(U.S.), Dario (U.S.), EmsiG GmbH Co. (Germany), Hangzhou Sejoy Electronics & Instruments (China), HemoCue AB (Sweden), iHealth Labs Inc. (U.S.), IME-DC GmbH (Germany), IN4 Technology Corp.(Taiwan), Integrity applications (Israel), Nemauro Medical Inc (U.K.) and Mediwise (U.K.), DiabetOmics, Inc. (U.S.) etc.

Mr. Satish Birudukota
IQ4I Research & Consultancy Pvt Ltd.,
+91-80-8147030229
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.